Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami Komrokji, Mina L Xu, Omar Abdel-Wahab, Justin Taylor, David P Steensma, Daniel T Starczynowski, Mikkael A Sekeres, Guillermo Sanz, David A Sallman, Gail J Roboz, Uwe Platzbecker, Mrinal M Patnaik, Eric Padron, Olatoyosi Odenike, Stephen D Nimer, Aziz Nazha, Ravi Majeti, Sanam Loghavi, Richard F Little, Alan F List, Tae Kon Kim, Christopher S Hourigan, Robert P Hasserjian, Stephanie Halene, Elizabeth A Griffiths, Steven D Gore, Peter Greenberg, Maria E Figueroa, Pierre Fenaux, Fabio Efficace, Amy E DeZern, Naval G Daver, Jane E Churpek, Hetty E Carraway, Rena Buckstein, Andrew M Brunner, Jacqueline Boultwood, Uma Borate, Rafael Bejar, John M Bennett, Andrew H Wei, Valeria Santini, Michael R Savona, Amer M Zeidan
The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we summarize these developments. We first critically examine the updated World Health Organization (WHO) classification and the International Consensus Classification (ICC) of MDS. We then compare traditional and molecularly based risk MDS risk assessment tools. Lastly, we discuss limitations of criteria in measuring therapeutic benefit and highlight how the International Working Group (IWG) 2018 and 2023 response criteria addressed these deficiencies and are endorsed by the icMDS...
August 19, 2023: Blood Reviews